MEDICAGO
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond to the needs of the global public health community and medical authorities and professionals.
“Taking on this new role with Medicago during this exciting time is a great honour for me,” said Mr. Nagao, President and Chief Executive Officer, Medicago. “I want our employees, investors, and stakeholders such as the Government of Canada to know that I will put all my efforts into seeing our COVID-19 and influenza vaccines through to a successful launch to protect as many people as possible.”
From 2007 to 2017, Mr. Nagao oversaw the establishment of Mitsubishi Tanabe Pharma Corporation’s U.S. presence and led the team that successfully achieved NDA of RADICAVA®, the first FDA-approved drug in over 20 years for the patients with Amyotrophic Lateral Sclerosis (ALS). Prior to that, Mr. Nagao was a Managing Director in investment banking at J.P. Morgan and Deutsche Bank where he was responsible for global clients and leading equity and cross-border M&A transactions in the pharmaceutical and biotechnology sector in North America, Japan and Europe. He has an MBA from Harvard Business School.
Mr. Nagao succeeds Dr. Bruce D. Clark, who held the position of President and CEO of Medicago since 2017 and was instrumental in the development of Medicago’s COVID-19 vaccine candidate.
Medicago recently announced the start of Phase 2/3 clinical trial of its plant-derived VLP vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity, based on the positive Phase 1 results and subsequent allowance to advance to Phase 2/3 by the Canadian regulatory authorities. The company is also building a new facility in Quebec to increase Canada’s domestic capacity for manufacturing vaccines, producing up to a billion doses annually.
“Medicago is at an inflection point. We are moving from a research and development focused organization to become a commercial entity supplying vaccines to Canadians and people around the world,” said Mr. Nagao.
About Medicago
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
To learn more about our plant-based technology: Video / Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uptime Institute Announces Five Data Center Predictions Report for 202613.1.2026 12:04:00 CET | Press release
As corporate AI moves beyond pilots and experimentation, infrastructure designers and operators face a series of big challenges spanning power, resiliency, sustainability and automation Uptime Institute today announced the release of its Five Data Center Predictions for 2026 looking beyond the more obvious trends of 2026 and examining some of the latest developments and challenges shaping the digital infrastructure industry. The 2026 predictions focus on the continued growth of the industry and related challenges, while also recognizing AI as a powerful, transformative accelerant to growth. While AI is the key driver for a wave of investment that will underpin digital infrastructure for decades to come, the speed and ultimate size of the build-outs are unclear at this time. “Critical digital infrastructure continues to expand strongly,” said Andy Lawrence, Executive Director of Research, Uptime Institute. “At the same time, our research shows uncertainty about how AI will reshape deman
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference13.1.2026 12:00:00 CET | Press release
Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton’s tyrosine kinase (BTK) inhibitors, as well as foundational hematology assets: sonrotoclax, a next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor that received its first global regulatory approvals on December 30, and BGB-16673, a potentially first-in-class and best-in-class BTK chimeric degradation activation compound (CDAC). I
BlueMatrix and Perplexity Partner to Bring AI-Powered Discovery to Institutional Research13.1.2026 12:00:00 CET | Press release
Partnership enables AI-assisted research while preserving BlueMatrix’s governance-first approach to integrating AI into regulated research environments. BlueMatrix, the global leader in capital markets content publishing technology, backed by Thoma Bravo, today announced a partnership with Perplexity to bring AI-enabled research and discovery to institutional investors using BlueMatrix’s governed, entitlement-aware framework. The partnership brings entitled broker research to Perplexity Enterprise users, enabling buy-side professionals to query their subscribed research content, alongside Perplexity’s broader capabilities, including real-time financial data, earnings transcripts, and deep research tools. Investment professionals and researchers can use natural language to surface relevant insights without changing existing data ownership, entitlements, or compliance structures. As buy-side teams increasingly turn to AI tools for research synthesis, a formal integration through BlueMatr
Vaudoise Becomes First Swiss Insurer to Go-Live with Guidewire Cloud Platform13.1.2026 11:21:00 CET | Press release
Vaudoise and Guidewire (NYSE: GWRE) have announced that Vaudoise has become the first Swiss insurer to go-live on Guidewire Cloud Platform. The company has successfully implemented Guidewire ClaimCenter and is currently integrating Guidewire PolicyCenter. By adopting Guidewire Cloud Platform, Vaudoise joins a global community of insurers focusing on insurance excellence with core modernization from a scalable, secure and rapidly updatable cloud delivery model. Arno Suess, Head of P&C Claims at Vaudoise, said: “We are very proud of this milestone, which sets a new benchmark for our industry. With Guidewire Cloud Platform, we can now process motor insurance claims faster, with greater automation and fully digital processes. The result: faster decisions, more transparency, and a seamless experience for customers during critical moments in their lives.” Mathias Grobet, EMEA VP at Guidewire, said: “Vaudoise is well-known for its customer focus, operational excellence and agility – qualities
Ant International Powered Over 2 Billion Transactions in its Core Emerging Markets in 2025, Expanding AI Payments and Digital Commerce Tools for Inclusive Growth13.1.2026 11:15:00 CET | Press release
150 million merchants across the world from Kuala Lumpur to London leverage Ant International’s solutions to reach local and global customers.In its main emerging markets, clients in Southeast Asia, South Asia, the Middle East and Latin America, including the SME sectors, recorded strong uplift through digital payments, cross-border commerce and banking solutions in 2025. Ant International supported over 2 billion digital cross-border transactions in 2025 for merchants in its core emerging markets including Southeast Asia (SEA), South Asia, the Middle East and Latin America (LATAM), as the company builds out a broader range of AI-powered digital financial and commerce solutions tailored to these regions’ diverse needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113850175/en/ Alipay+ now connects more than 1.8 billion user accounts across 40 international payment partners to merchants across more than 100 markets Ant I
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom